Research programme: calcium channel modulators - Biogen
Alternative Names: Cav2.2 - Biogen; Cav2.2 modulators - BiogenLatest Information Update: 16 Jul 2016
At a glance
- Originator Calchan; GlaxoSmithKline
- Developer Convergence Pharmaceuticals
- Class Analgesics; Small molecules
- Mechanism of Action Calcium channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pain
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pain in United Kingdom
- 06 Oct 2010 Preclinical trials in Pain in United Kingdom (unspecified route)